Shaping the future of obesity care

Over the last few years, GLP-1 and next-generation anti-obesity medicines have moved from specialist care into one of the most important global health trends. These treatments can deliver clinically meaningful weight loss, and the category is expected to grow significantly in the coming years.

 

A major problem is being solved — and a new support need is emerging.

Modern obesity treatments work partly by reducing appetite and calorie intake. Total calorie intake may fall by 16–39%, which is central to weight loss — but it also changes the gut environment. Less food intake, altered nutrient patterns, delayed gastric emptying and common digestive side effects create new needs around gut health, digestive comfort, nutritional resilience and long-term wellbeing.

That is why Azento Health is developing azh-biotics^® — a microbiome-based companion platform designed to support people before, during and after their weight-loss journey.